Professor of Medicine and Epidemiology
Principal Investigator, AIDS Clinical Research Group
The University of North Carolina at Chapel Hill
Chapel Hill, North Carolina
- Combination antiretroviral therapy
- Antiretroviral drug development
- HIV resistance
- HIV-1 penetration into tissue compartments
- HIV-1 primary infection
Dr Eron is the Director of the Clinical Core at the Center for AIDS Research at the University of North Carolina at Chapel Hill. He is also the Associate Director of the Clinical Trials Research Center and Principal Investigator of the AIDS Clinical Research Group.
- Member, IAS–USA Antiretroviral Guidelines Committee (2007-present)
- Elizabeth Glaser Award Advisory Board, Pediatric AIDS Foundation
- Edward Weisband Distinguished Alumnus Award for Public Service, SUNY Binghamton (2005)
- Lifetime Member, International Association of Physicians in AIDS Care (IAPAC) (2005)
- UNC-CH Distinguished Teaching Award for Post-Baccalaureate Instruction (2005)
- Alpha Omega Alpha, Medical Honor Society (nominated by UNC Medical Students) (2000)
- UNC-CH Junior Faculty Development Award (1995)
- Medicine Housestaff Teaching Award at University of North Carolina, Chapel Hill (1994)
- State University of New York at Binghamton, BS Biochemistry (1980)
- Harvard Medical School, MD (1984)
- Massachusetts General Hospital, Residency, Internal Medicine (1984–1987)
- Massachusetts General Hospital, Fellowship, Infectious Diseases (1989–1992)
- Eron JJ, Young B, Cooper DA, et al. Switch to a raltegravir-based regimen versus continuation of a lopinavir-ritonavir-based regimen in stable HIV-infected patients with suppressed viraemia (SWITCHMRK 1 and 2): two multicentre, double-blind, randomised controlled trials. Lancet. 2010;375:396-407.
- Cole SR, Napravnik S, Mugavero MJ, Lau B, Eron JJ Jr, Saag MS. Copy-years viremia as a measure of cumulative human immunodeficiency virus viral burden. Am J Epidemiol. 2010;171:198-205.
- Gandhi RT, Bosch RJ, Aga E, et al. No evidence for decay of the latent reservoir in HIV-1-infected patients receiving intensive enfuvirtide-containing antiretroviral therapy. J Infect Dis. 2010;201:293-296.
- Gandhi RT, Zheng L, Bosch RJ, et al. The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial. PLoS Med. 2010;7. pii: e1000321.
- Eron JJ Jr, Park JG, Haubrich R, et al. Predictive value of pharmacokinetics-adjusted phenotypic susceptibility on response to ritonavir-enhanced protease inhibitors (PIs) in human immunodeficiency virus-infected subjects failing prior PI therapy. Antimicrob Agents Chemother. 2009;53(6):2335-2341.
- Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009;360:1815-1826.
The 2017 Ryan White HIV/AIDS Program (RWHAP) Clinical Conference
Improving the Management of HIV Disease®: An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management
Webcasts of the The Clinical Pathway Track of the 2016 National Ryan White Conference on HIV Care & Treatment
An Advanced CME Live Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management
An Advanced CME Course in HIV Pathogenesis, Antiretrovirals, and Other Selected Issues in HIV Disease Management
14th Annual Clinical Conference for the Ryan White HIV/AIDS Program
Günthard HF, Saag MS, Benson CA, del Rio C, Eron JJ, Gallant JE, Hoy JF, Mugavero MJ, Sax PE, Thompson MA, Gandhi RT, Landovitz RJ, Smith DM, Jacobsen DM, Volberding PA. Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults 2016 Recommendations of the International Antiviral Society–USA Panel. JAMA. 2016.